The first in vitro experiments of CLL1-CAR by Tashiro et al. demonstrated a high efficacy in killing AML blasts without damaging healthy HSCs, allowing immune recovery after therapy [72]. The gene discussed is CLEC12A; the disease is acute myeloid leukemia.